| 產(chǎn)品名稱 |
SNU-387 |
| 商品貨號 |
B165736 |
| Organism |
Homo sapiens, human |
| Tissue |
liver |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent |
| Biosafety Level |
2 [Cells contain Hepatitis B virus]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
grade IV/V, pleomorphic hepatocellular carcinoma |
| Age |
41 years |
| Gender |
female |
| Ethnicity |
Asian |
| Storage Conditions |
liquid nitrogen vapor phase |
| Karyotype |
aneuploid; modal number = 67 |
| Derivation |
SNU-387 was derived in 1990 by J.-G. Park and associates from a primary hepatocellular carcinoma taken from a Korean patient who had been treated by transcatheter arterial embolization with lipoidol plus a combination of doxorubicin and mitomycin-C.
Tumor cells were initially cultured in ACL-4 medium supplemented with 5% heat-inactivated fetal bovine serum. After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum. |
| Clinical Data |
41 years
Asian
female
|
| Antigen Expression |
Blood Type O; Rh + |
| Comments |
Grossly, the original tumor was single nodular.
Histologically, it was predominantly compact and minor trabecular type.
The cultured cells contain a single nucleus.
Hepatitis B virus (HBV) DNA was detected by Southern blot hybridization.
HBV genomic RNA was not expressed.
|
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C
Subculture Ratio: 1:3 to 1:6
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994.
|
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 13,14 D13S317: 12 D16S539: 9 D5S818: 10,12 D7S820: 8,10 THO1: 7 TPOX: 8,9 vWA: 14,16 |
| Population Doubling Time |
61 hrs |
| Name of Depositor |
J Park |
| Deposited As |
Homo sapiens |
| Product Origin |
http://prod-cms.atcc.org/sitecore/shell/Applications/Content%20editor.aspx# |
| Year of Origin |
1990 |
| References |
Park JG, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 62: 276-282, 1995. PubMed: 7543080
|
